Compare MIR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | BLCO |
|---|---|---|
| Founded | 2005 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | MIR | BLCO |
|---|---|---|
| Price | $26.98 | $17.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 14 |
| Target Price | ★ $28.29 | $17.31 |
| AVG Volume (30 Days) | ★ 2.1M | 332.5K |
| Earning Date | 02-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | $902,300,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $8.75 | $8.06 |
| Revenue Next Year | $23.17 | $5.79 |
| P/E Ratio | $265.31 | ★ N/A |
| Revenue Growth | ★ 7.82 | 6.23 |
| 52 Week Low | $12.00 | $10.45 |
| 52 Week High | $30.28 | $18.14 |
| Indicator | MIR | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 56.07 |
| Support Level | $26.01 | $17.18 |
| Resistance Level | $27.40 | $17.86 |
| Average True Range (ATR) | 0.88 | 0.42 |
| MACD | 0.36 | -0.02 |
| Stochastic Oscillator | 90.75 | 64.63 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.